For the rheumatologist, one of the greatest challenges since the start of the coronavirus disease 2019 (COVID-19) pandemic has been determining which of our patients are at greatest risk for severe COVID-19, and who should be triaged for aggressive outpatient management with preexposure prophylaxis (PrEP), additional vaccine doses, and treatment with antivirals and/or monoclonal antibody products when infected. At present, although the US federal government declared an end to the public health emergency for COVID-19 in May 2023, SARS-CoV-2 is still with us.

中文翻译：

---

COVID-19 对免疫介导的炎症性疾病患者的未来：谁面临风险？

对于风湿病学家来说，自 2019 年冠状病毒病 (COVID-19) 大流行开始以来，最大的挑战之一是确定我们的哪些患者感染严重 COVID-19 的风险最大，以及哪些患者应该接受积极的门诊治疗分类暴露前预防 (PrEP)、额外疫苗剂量以及感染时使用抗病毒药物和/或单克隆抗体产品进行治疗。目前，尽管美国联邦政府于 2023 年 5 月宣布结束 COVID-19 公共卫生紧急状态，但 SARS-CoV-2 仍然存在。